DuraSite

DuraSite®

Ophthalmology A sustained-release system designed to permit the gradual release of a drug into the eye over a period of hrs, overcoming problems common with conventional drug delivery
References in periodicals archive ?
InSite Vision added that it is advancing new specialty ophthalmic products for the treatment of diseases affecting the front and back of the eye.It has two commercial products based on its innovative DuraSite platform approved for the treatment of bacterial eye infections, AzaSite (azithromycin ophthalmic solution) 1%, marketed in the US by Akorn and Besivance (besifloxacin ophthalmic suspension) 0.6%, marketed by Bausch + Lomb, a wholly owned subsidiary of Valeant Pharmaceuticals.
The company has two commercial products based on its innovative DuraSite platform approved for the treatment of bacterial eye infections, AzaSite (azithromycin ophthalmic solution) 1%, marketed in the US by Akorn, Inc., and Besivance (besifloxacin ophthalmic suspension) 0.6%, marketed by Bausch and Lomb, a wholly owned subsidiary of Valeant Pharmaceuticals International.
It was reported yesterday that the contract has been signed for the development and commercialisation of InSite's innovative ophthalmic therapeutic products, AzaSite (one percent azithromycin), AzaSite Xtra (two percent azithromycin) and BromSite (0.075 percent bromfenac) all formulated in InSite's DuraSite drug delivery system.
Azithromycin in DuraSite for the treatment of blepharitis.
AzaSite Plus and DexaSite are formulated with the company's proprietary DuraSite drug delivery platform: AzaSite Plus combines dexamethasone 0.1% with the antibiotic AzaSite (azithromycin 1% ophthalmic solution) in DuraSite and DexaSite combines dexamethasone 0.1% with DuraSite.
ISV-401 combines azithromycin with DuraSite, the company's patented drug-delivery vehicle that offers the benefits of prolonged release of an active ingredient.
InSite Vision's products utilize a patented ophthalmic drug delivery system known as DuraSite.
Ophthalmologic company InSite Vision (Other OTC:INSV) reported on Wednesday the receipt of the US Patent Number 8,778,999 covering Bromfenac Non-Steroidal Ophthalmic Compositions Formulated in DuraSite from the US Patent and Trademark Office (USPTO).
The competitive landscape has resulted in number of sustained ere; Alkermes, Prolease, Medisorb), Oral (MacroMed, SQ2Gei; Altus Biologics, Crystalized proteins; Alkermes, PLG microspheres; Spherics, sticky spheres; DepoMed, GR System), Ocular (InSite Vision, Durasite polymer eye drops), and Pulmonary areas too (Acusphere, microspheres; Alkermes, AIR microparticles) (2).
ISV-205 uses the company's proprietary DuraSite drug-delivery technology, which also is incorporated into the company's ocular infection programs ISV- 401 and ISV-403, and the company's retinal program.